WAVE Life Sciences (WVE) Misses Q3 EPS by 17c, Revenues Miss

WAVE Life Sciences (NASDAQ: WVE) reported Q3 EPS of ($0.86), $0.17 worse than the analyst estimate of ($0.69). Revenue for the quarter came in at $3.45 million versus the consensus estimate of $11.55 million.

"Equinox Gold again delivered record results with more than 128,000 ounces of gold sold, $98 million in earnings from mine operations and adjusted net income of $39 million," said Christian Milau, Chief Executive Officer. "Proactive COVID-19 testing and enhanced health and safety protocols have allowed us to safely operate our mines while protecting both the health and economic wellbeing of our workforce and local communities. Unfortunately, a community blockade has temporarily suspended operations at Los Filos. We have been meeting with the community to understand and discuss their concerns and continue to seek a long-term solution so Los Filos can resume normal operations and continue to provide benefits to all stakeholders.

"We continue to deliver on our organic growth projects, which will bring additional production and cash flow to the Company. We commenced production at our seventh gold mine in October with first gold pour at Castle Mountain, and advanced the Castle Mountain Phase 2 expansion study with results expected in Q1 2021. We have also commenced full construction of the Santa Luz project in Brazil, which will add 100,000 ounces of annual gold production for an initial 9.5-year mine life."

For earnings history and earnings-related data on WAVE Life Sciences (WVE) click here.

You May Also Be Interested In

• AbbVie updates 2026 EPS guidance after $291M IPR&D charge
• Samsung 2q Oper Profit 89.40t Won, Est. 84.2t Won
• SEALSQ reports 120% revenue growth in H1 2026, reaffirms guidance